Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ascletis Pharma, Inc. ( (HK:1672) ) has issued an announcement.
Ascletis Pharma Inc. has completed dosing all participants in its U.S.-based clinical study evaluating the combination of its adipose-targeted, ultra-long-acting small molecule THR β agonist, ASC47, with semaglutide for obesity treatment. The study aims to assess the safety, tolerability, and preliminary efficacy of this combination, with topline data expected in the fourth quarter of 2025. The rapid enrollment of participants highlights the interest in new obesity treatments and the potential benefits of combination therapies, which could enhance Ascletis’s industry positioning and offer significant implications for stakeholders.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a pharmaceutical company focused on developing innovative therapies, particularly in the field of obesity treatment. The company is known for its in-house discovery and development of small molecule agonists targeting specific receptors, with a market focus on addressing unmet medical needs in the obesity sector.
Average Trading Volume: 5,744,330
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.59B
See more data about 1672 stock on TipRanks’ Stock Analysis page.